share_log

ESSA Pharma Slides As Insider Purchases Lose Another US$211k

ESSA Pharma Slides As Insider Purchases Lose Another US$211k

essa pharma内部人员购买额外21.1万美元后股价下滑
Simply Wall St ·  2024/11/04 08:18

Insiders who bought US$289.3k worth of ESSA Pharma Inc.'s (NASDAQ:EPIX) stock at an average buy price of US$5.17 over the last year may be disappointed by the recent 74% decrease in the stock. This is not good as insiders invest based on expectations that their money will appreciate over time. However, as a result of recent losses, their original investment is now worth only US$78.4k.

在过去一年里,买入essa pharma股票总价值28.93万美元,平均购入价为5.17美元的内部人士,可能对股价最近下跌74%感到失望。内部人士根据对钱财会随时间增值的预期而投资,但由于最近的亏损,他们的原始投资现在仅值7.84万美元。

While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we would consider it foolish to ignore insider transactions altogether.

虽然我们永远不会建议投资者仅基于公司董事已经做出的决策而做出决策,但同时我们认为完全忽略内部交易是愚蠢的。

ESSA Pharma Insider Transactions Over The Last Year

过去一年中,essa pharma内部交易

In the last twelve months, the biggest single purchase by an insider was when Independent Director Franklin Berger bought US$135k worth of shares at a price of US$5.73 per share. That means that an insider was happy to buy shares at above the current price of US$1.40. It's very possible they regret the purchase, but it's more likely they are bullish about the company. To us, it's very important to consider the price insiders pay for shares. Generally speaking, it catches our eye when insiders have purchased shares at above current prices, as it suggests they believed the shares were worth buying, even at a higher price.

在过去十二个月中,内部人士中最大的单笔购买是独立董事Franklin Berger以5.73美元每股的价格购入价值13.5万美元的股票。这意味着内部人士乐意以高于当前价格1.40美元购买股票。他们很可能后悔购买,但更可能是对该公司看好。对我们来说,考虑内部人员购买股票的价格非常重要。一般来说,当内部人员以高于当前价格购入股票时,我们会着眼,因为这表明他们认为这些股票值得购买,即使价格更高。

ESSA Pharma insiders may have bought shares in the last year, but they didn't sell any. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!

essa pharma内部人士可能在过去一年里购买了股票,但他们没有卖出任何股票。您可以在下面的图表中看到内部交易(由公司和个人)在过去一年的情况。点击下面的图表,您可以看到每笔内部交易的详细信息!

big
NasdaqCM:EPIX Insider Trading Volume November 4th 2024
纳斯达克CM:EPIX内幕交易量2024年11月4日

ESSA Pharma is not the only stock that insiders are buying. For those who like to find small cap companies at attractive valuations, this free list of growing companies with recent insider purchasing, could be just the ticket.

essa pharma并非唯一一家内部人员在购买股票的公司。对于那些喜欢找到估值吸引人的小盘公司的人,这份最新内部人员购买的增长型公司免费名单可能正合你意。

Insider Ownership Of ESSA Pharma

essa pharma内部持股

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. A high insider ownership often makes company leadership more mindful of shareholder interests. Our data suggests ESSA Pharma insiders own 2.2% of the company, worth about US$1.4m. I generally like to see higher levels of ownership.

查看一家公司内部人员的总持股量,有助于判断他们与普通股东的是否利益一致。高比例的内部持股往往使公司领导更加关注股东利益。我们的数据显示,essa pharma的内部人员拥有公司2.2%的股份,价值约140万美元。我通常希望看到更高比例的持股。

So What Do The ESSA Pharma Insider Transactions Indicate?

那么,essa pharma内部交易究竟意味着什么?

There haven't been any insider transactions in the last three months -- that doesn't mean much. On a brighter note, the transactions over the last year are encouraging. We'd like to see bigger individual holdings. However, we don't see anything to make us think ESSA Pharma insiders are doubting the company. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. Every company has risks, and we've spotted 4 warning signs for ESSA Pharma (of which 2 shouldn't be ignored!) you should know about.

过去三个月内没有任何内部交易——这并没有太大意义。值得一提的是,过去一年的交易情况令人鼓舞。我们希望看到更大的个人持股。但是,我们并没有发现任何迹象表明essa pharma的内部人员对公司存疑。因此,了解内部人员是在买入还是卖出固然有帮助,但了解特定公司面临的风险也是很有帮助的。每家公司都存在风险,而我们已经发现essa pharma存在4个警示信号(其中有2个不容忽视!)你应该知道的。

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

如果您想查看另一家公司的信息-一家潜在具有优秀财务状况的公司-请不要错过这个带有高股权回报率和低债务的有趣公司免费列表。

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

对于本文而言,内部人是指向相关监管机构报告其交易的个人。我们目前仅考虑公开市场交易和直接利益的私人处置,但不包括衍生交易或间接利益。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对本文有任何反馈?对内容有任何疑虑?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发